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ABSTRACT
Predicting the response to immunosuppressive therapy could provide useful information for clinician to make the strategies for treating patients with aplastic anemia. In our current study, we evaluated the relationship between telomere length of lymphocytes at diagnosis and the response to immunosuppressive therapy in 64 children with aplastic anemia, using flow-fluorescence in situ hybridization. The median age of patients was 10 years (range, 1.5 to 16.2 years). Severity of the disease was classified as very severe in 23, severe in 21, and moderate in 20 patients. All patients were enrolled in multicenter studies with antithymocyte globulin and cyclosporine. The response rate to immunosuppressive therapy at 6 months was 52% (33/64). The probability of 5-years failure free survival and overall survival were 56% (95% confidence interval, 41 -69%) and 97% (87 -99%). The median of telomere length in responders was -0.4 standard deviation (-2.7 to +3.0 standard deviation), whereas -1.5 standard deviation (-4.0 to +1.6 standard deviation) in non-responders (P<0.001). Mulitivariate analysis revealed that telomere length
Introduction
Aplastic anemia (AA) is defined as bone marrow aplasia and peripheral blood pancytopenia; disease pathogenesis is thought to involve immune mediated processes. The first choice of treatment for severe AA in children is hematopoietic stem cell transplantation from the human leukocyte antigen (HLA)-matched sibling donor 1, 2 . However, 60 to 70% of children with severe AA have no matched sibling donor and receive immunosuppressive therapy (IST), consisting of antithymocyte globulin (ATG) and cyclosporine (CyA). According to previous studies in children, the response rate to IST at 6 months was 60 to 70%, with the probability of survival at 5 years being greater than 90%. On the other hand, relapses occur in 10-30% of patients who responded to IST and clonal evolution develops in 10-15% of overall patients [3] [4] [5] . In adults, several pre-treatment biomarkers have been proposed as promising tests for predicting favorable response to IST including the presence of either human leukocyte antigen (HLA)-DR15 or a minor population of paroxysmal nocturnal hemoglobinuria (PNH)-type cells 6-9 . However, we previously reported that both tests were not useful predictors of the response to IST and that lower white blood cell count and shorter interval from diagnosis to IST were significant predictive marker of better response 10 , on the other hand NIH study revealed that higher baseline absolute reticulocyte count and lymphocyte count were highly predictive of response to IST in adult patients 11 . These results suggest a different etiology of AA between adults and children 10 .
Dyskeratosis congenita (DC) is a rare inherited disease characterized by the classical mucocutaneous triad of abnormal skin pigmentation, nail dystrophy, and mucosal leucoplakia 12 . Patients with DC are unable to maintain the telomere complex that are protein-DNA structures at the end of eukaryotic chromosomes that prevent degradation and aberrant recombination of the chromosome ends 13, 14 , and consequently have very short telomeres 15 .
Shortened 
Methods

Patients
Peripheral blood samples at diagnosis and clinical records were obtained from 64 children who fulfilled entry criteria and enrolled in two prospective studies conducted by the Japan Childhood Aplastic Anemia Study Group 26, 27 . Patients with acquired AA were eligible if the following criteria were satisfied (Detail of the criteria was described in supplemental methods). Thirty-eight patients received horse ATG (Lymphoglobulin; Genzyme, Cambridge, MA, USA) at 15mg/kg/day for 5 days and 26 received rabbit ATG (Thymoglobulin, Genzyme, Cambridge, MA, USA) at 3.75 mg/kg/day for 5 days. CyA (6mg/kg/day, orally) was started on day1 and continued to at least day 180. The dose was adjusted to achieve a whole blood trough level of 100 to 200ng/ml. Standard supportive care was supplied in each institute. Response to IST was evaluated according to previously described criteria 3 . We defined patients with complete response or partial response at 6 months after IST as responders, and the other patients as non-responders. Relapse was defined by conversion to no response from a partial or complete response and/or the requirement for blood transfusions.
All samples and clinical records were collected after written informed consent obtained according to protocols approved by the Ethics Review Committee, Nagoya University Graduate School of Medicine (Research #732).
Measurements of telomere length and population of PNH clones
The average relative telomere length (RTL) of peripheral lymphocytes was measured by flow-fluorescence in situ hybridization (flow-FISH), using a
Telomere PNA kit (Dako Cytomation, Glostrup, Denmark) 28 . Lymphocytes were derived from fresh peripheral blood in 38 cases and from frozen stored peripheral blood in 26 cases. We used delta RTL to compare patient's telomere length and age-matched healthy controls. Detail of methods for measuring telomere length and definition of delta RTL were described in supplemental methods.
A minor population of paroxysmal nocturnal hemoglobinuria (PNH)-type granulocytes and red blood cells were also evaluated by flow cytometry according to the previously described method 10 .
Statistical analysis
We analyzed predictive variables associated with response to IST, failure-free survival (FFS; in which relapse, clonal evolution, second IST, HSCT, and death were censored), transplantation-free survival (TFS; in which HSCT and death were censored), and overall survival (OS). Pre-treatment variables included gender, patient age, etiology, disease severity, interval from diagnosis to IST, leukocyte count, lymphocyte count, neutrophil count, hemoglobin (Hb) level, platelet count, reticulocyte count, presence of HLA-DR15, presence of minor PNH clone, and delta RTL. Differences in these variables between responder and non-responder patients were assessed using the Mann-Whitney U-test and the Fisher exact probability test. Predictive factors with a p-value <0.10 in the univariate analyses were set in the multivariate analysis (logistic regression modeling). P-values of <0.05 were considered statistically significant. Measures of association were expressed as hazard ratios (HR) with 95% confidence intervals (CI). All tests were two-tailed with a type I error of less than 0.05 considered for indicating statistical significance. All analyses were performed using STATA12.0 software (STATA, College Station, TX, USA).
Results
Pre-treatment patients' characteristics and clinical outcomes
A total of 64 patients with AA were included in this study ( Table 1 months, ranging from 6 to 132 months.
Overall, 33 of 64 patients (58%) responded to IST at 6 months after administration of ATG. Of the 33 responders, 4 children relapsed at 6, 34, 66, and 91 months after IST, respectively. The probability of 5-years cumulative incidence of relapse was 8% (95% CI, 2 -28%). Nineteen transplantations were carried out for non-responders or patients with relapse. Of 64 children with AA, only 1 patient developed clonal evolution at 23 months after IST. During observation, 2 patients died; both of them showed no response to IST, one suffered from lethal cerebral hemorrhage at 6 months, and the other underwent bone marrow transplantation from HLA matched unrelated donor at 12 months after IST and died of transplantation related hepatic failure. The probability of 5-years FFS, TFS, and OS were 56% (95% CI, 41 -69%), 63% (95% CI, 48 -75%), and 97% (95% CI, 87 -99%).
Telomere length of children with AA
Comparing with SD calculated in 71 healthy individuals, the median of telomere length was -0.9SD (range, -4.0 to +3.0SD) in all patients (n=64), -0.4SD (range, -2.7 to +3.0SD) in responders (n=33), and -1.5SD (range, -4.0 to +1.6SD) in non-responders (n=31) ( Figure 1A and 1B). There was a significant difference in telomere length between responders and non-responders (P<0.001). We evaluated the effects of age-adjusted telomere length quartiles on the response rate. There was a significant relationship between hematologic responseand telomere length. The response rates at 6months were 12.5% in the first (the shortest), 37.5% in the second, 75%in the third, and 81.3% in the fourth (the longest) quartiles of telomere length ( Figure 2 ). The most powerful cut-off point for dividing responders and non-responders by telomere length was -1.0SD
(P=6.9x10 -6 ). There was no statistical tendency between relapse rate / clonal evolution / overall survival and telomere length.
We evaluated the pre-treatment variables for predicting response to IST in 64 children with AA (Table 1) . In an univariate analysis, interval from diagnosis to IST longer than 25 days (P=0.01), platelet count at diagnosis less than 25x10 9 /L (P=0.01), and telomere length shorter than -1SD (P<0.001) were found to be the variables statistically significant for poor response to IST, while there were no significant differences between responders and non-responders in were the significant predictive variables for poor response to IST (Table2).
Discussion
Our study demonstrated that the measurement of telomere length of lymphocytes is useful for predicting the response to IST in patients with AA.
Recently, a report from NIH group described that the telomere length of peripheral blood leukocytes was not related to hematologic response to IST, but was associated with the high risk of hematologic relapse, clonal evolution to myelodysplastic syndrome, and overall survival 25 . Several reasons may explain the conflicting results of the two studies. There are several differences between the current study and the NIH study, including the methods of telomere length measurement and patients' characteristics.
In the NIH study, the telomere length of pre-treatment total leukocytes was assessed by quantitative polymerase chain reaction (PCR). We measured the telomere length of lymphocytes using flow-FISH, which enabled us to measure median telomere length in the subpopulations of blood cells. Alter et al.
compared the diagnostic sensitivity and specificity of short telomeres in different subpopulations of blood cells 29 . Their results indicated that lymphocytes were more suitable for diagnosis of DC than total leukocytes, which were a heterogeneous mixture of cell population. The proportions of each cell population were different in each patient. The use of total leukocytes is suspected to provide less consistent results than analyses of defined leukocyte subpopulations.
Another difference between the two studies was the distribution of patients' age. Patients in our study were much younger than those in the NIH study (mean ages; 10 years versus 35 years, respectively). Because telomeres shorten with regard to age 30 , the differences in telomere length between patients and healthy individuals may become smaller in adults than in children.
Moreover, in the NIH study, the cohort was restricted to patients with severe AA, and patients with moderate AA were not included. In contrast, 20 of 64 AA patients in our study had moderate disease. We could not estimate the frequency of clonal evolution since the patient who evolved into myelodysplastic syndrome during observation was only one in our cohort.
The causes of the difference in telomere length between responders and non-responders remain unknown. The short telomere length in non-responders may be ascribed to the presence of cryptic forms of IBMFS in the study cohort. Alter et al. reported that nearly all of the patients with both typical and cryptic DC have very short telomeres, as low as the first percentile of normal controls 25 . In our previous study, the RTLs of lymphocytes were below the 5 % of normal controls in all of 6 DC patients and 2 AA patients harboring TERT mutation 31 . In the current study, there were 10 AA patients with shorter telomere length than -2.0 SD of healthy cohort, but none of them showed clinical features of DC and had any mutation in DKC1, TERC, TERT, NOP10, TINF2, and TCAB1. It is unlikely that short telomeres in non-responders to be ascribed to the presence of a cryptic form of DC.
Another possibility is that short telomere length may be a surrogate maker for longer disease duration which damage the hematopoietic stem cells and cause higher number of compensatory stem cell divisions. We recently reported a significant inverse correlation between response rate to IST and interval between diagnosis and treatment in a large cohort of 312 children with newly diagnosed AA 32 . It is often difficult to determine the exact date of onset of the disease in patients with AA, especially in patients with moderate AA. The shorter telomere length may simply reflect longer duration of the disease in non-responders.
However, our study has several limitations, including heterogeneous population, relatively small number of patients and short follow-up period. To validate the results, we are conducting a prospective study to determine the optimal use of rabbit ATG for severe AA, in which we evaluate the relationship between telomere length of lymphocytes at diagnosis and the response to IST.
In conclusion, measurement of the telomere length in lymphocytes by flow-FISH is a promising assay not only for identifying cryptic DC but also in predicting the response to IST of patients with AA.
Authorship and Disclosures
HS and NN were the principal investigators, performed the laboratory work, gathered clinical information, participated in the statistical analysis, wrote the paper, and take primary responsibility for the paper; XW, AN, SD, and YX performed the laboratory work for this study; AH, HMu, NY, KK, HMo, KN, and HY gathered clinical information; YT, RK, EI, HY, SO, and AO coordinated the research; SK directed the research and wrote the paper.
The authors supported by a grant from the Research Commitee for the dyskeratosis congenita, Ministry of Halth, and Walfare of Japan (H23-Nanchi-Japan-099) and a grant from Sanofi K.K.. RET, reticulocyte count; RTL, relative telomere length; SAA, severe aplastic anemia; SD, standard deviation; VSAA, very severe aplastic anemia; WBC, white blood cell count. 
Table1. Patients chracteristics
Supplemental Methods
Patients
Patients with acquired aplastic anemia (AA) were eligible if the following criteria were satisfied: age under 18 years, newly diagnosed disease without specific prior treatment, moderate to very severe AA, and no genetic mutation in DKC1, TERC, TERT, NOP10, TINF2, and TCAB1 by Sanger sequencing method despite of shorter telomere than -2 standard deviation (SD) of healthy cohort.
Primers for each gene were listed in supplemental table 1.
Measurements of telomere length and population of PNH clones
The analysis was performed using the FACS Calibur flow cytometer Figure   1A ). Delta RTLs were expressed as distances from the age-appropriate point on the normal regression line of RTL versus age (Supplemental Figure 1B) 
